rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
8 Pt 1
|
pubmed:dateCreated |
2008-8-13
|
pubmed:abstractText |
Proton pump inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1440-1746
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1287-91
|
pubmed:meshHeading |
pubmed-meshheading:18637061-2-Pyridinylmethylsulfinylbenzimidazoles,
pubmed-meshheading:18637061-Adult,
pubmed-meshheading:18637061-Amoxicillin,
pubmed-meshheading:18637061-Anti-Bacterial Agents,
pubmed-meshheading:18637061-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:18637061-Clarithromycin,
pubmed-meshheading:18637061-Drug Therapy, Combination,
pubmed-meshheading:18637061-Female,
pubmed-meshheading:18637061-Helicobacter Infections,
pubmed-meshheading:18637061-Helicobacter pylori,
pubmed-meshheading:18637061-Humans,
pubmed-meshheading:18637061-Male,
pubmed-meshheading:18637061-Middle Aged,
pubmed-meshheading:18637061-Omeprazole,
pubmed-meshheading:18637061-Polymorphism, Genetic,
pubmed-meshheading:18637061-Proton Pump Inhibitors,
pubmed-meshheading:18637061-Treatment Outcome
|
pubmed:year |
2008
|
pubmed:articleTitle |
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
|
pubmed:affiliation |
Department of Internal Medicine and Liver Research Institute, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|